Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
Allorion Therapeutics’ Licensing Agreement with Avenzo Therapeutics
LianBio’s License Agreement with Bristol Myers Squibb
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
Beijing Fourth Paradigm Technology’s $150 Million Initial Public Offering
O’Melveny represented the sole sponsor, the coordinators and the underwriters in the transaction. Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) announced its initial public offering and listing...
HUTCHMED’s License Agreement with Takeda Pharmaceutical
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
Beauty Farm’s Hong Kong IPO and Listing
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...
3D Medicines Inc.’s Listing on the Stock Exchange of Hong Kong
Herbert Smith Freehills advised CICC and CSCI on the deal while O’Melveny recently represented 3D Medicines. CICC and CSCI acted as joint sponsors of 3D Medicines...
Bain Capital’s Acquisition of a Majority Stake in Classys
Ropes & Gray represented Bain Capital Private Equity in the transaction. Bain Capital Private Equity executed its acquisition, and related financing, of a majority stake in...
Huadong Medicine’s Collaboration with Kiniksa Pharmaceuticals
Greenberg Traurig represented Huadong Medicine on the deal, while Ropes & Gray advised Kiniksa Pharmaceuticals. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of...
Yonghe Medical Group Co.’s US$192 Million Hong Kong IPO
O’Melveny & Myers LLP advised Yonghe Medical on the deal. Yonghe Medical Group Co., Ltd. (2279.HK) announced its HK$1.49 billion (approximately US$192 million) initial public offering and...
LianBio’s $325 Million Initial Public Offering
Zhong Lun and Ropes & Gray advised LianBio on the deal. LianBio executed an initial public offering and listing of American depositary shares on the Nasdaq...
Acotec Scientific Holdings Limited’s HK$1.529 Billion Hong Kong Initial Public Offering
Herbert Smith Freehills has advised Morgan Stanley and CICC on the matter while O’Melveny & Myers and Maples and Calder represented Acotec Scientific Holdings Limited. The...
Boston Scientific’s $1.07 Billion Acquisition of Lumenis Surgical Business
Ropes & Gray represented an affiliate of Baring Private Equity Asia in the transaction, while Yigal Arnon & Co. and Latham & Watkins represented Boston Scientific,...